Novel Treatment Paradigms: Complement Inhibition in Antineutrophil Cytoplasmic Autoantibody Vasculitis

Area of Science:

• Immunology
• Nephrology
• Rheumatology

Background:

• The alternative complement pathway is crucial in ANCA vasculitis pathogenesis.
• Complement activation fragments can serve as biomarkers for disease monitoring.
• C5a receptor antagonism is a key therapeutic strategy.

Purpose of the Study:

• To review clinical developments and trials of complement inhibition in ANCA vasculitis.
• To discuss the efficacy and safety of avacopan and other complement inhibitors.
• To identify limitations and future research directions for complement-targeted therapies.

Main Methods:

• Review of clinical developments and pivotal clinical trials.
• Analysis of studies evaluating complement inhibitors in ANCA vasculitis.
• Summary of findings on avacopan's efficacy and safety.

Main Results:

• Avacopan reduces disease activity, proteinuria, and glucocorticoid exposure.
• Avacopan may improve kidney recovery in severe ANCA vasculitis.
• Emerging complement inhibitors show potential for ANCA vasculitis treatment.

Conclusions:

• Complement inhibitors offer potential for more effective and safer ANCA vasculitis treatments.
• Limitations and barriers exist for widespread use of complement inhibitors.
• Further research is essential to optimize the integration of complement inhibition into treatment paradigms.